Clinical Trial Update: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dosimetry, randomized dose optimization, dose escalation, and efficacy of Ac-225 Rosopatamab Tetraxetan in PSMA PET-positive c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Ac-225 Rosopatamab Tetraxetan

Snippet

Sponsor: Convergent Therapeutics | Conditions: PSMA PET-Positive Castration-Resistant Prostate Cancer | Phase 2 | Status: RECRUITING